



Imjudo® (Tremelimumab-actl) Prior Authorization Form

Member Name: _____ **Date of Birth:** _____ **Member ID#:** _____

Drug Information

Physician billing (HCPCS code: _____ **) Start Date (or date of next dose):** _____

Dose: _____ **Regimen:** _____

Billing Provider Information

Provider NPI: _____ **Provider Name:** _____

Provider Phone: _____ **Provider Fax:** _____

Prescriber Information

Prescriber NPI: _____ **Prescriber Name:** _____

Prescriber Phone: _____ **Prescriber Fax:** _____ **Specialty:** _____

Criteria

For Initial Authorization:

1. Please indicate the diagnosis and information:

Non-Small Cell Lung Cancer (NSCLC)

A. Does the member have metastatic disease? Yes ___ No ___

B. Is there an epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 mutations? Yes ___ No ___

C. Will tremelimumab-actl be given in combination with durvalumab and platinum-based chemotherapy? Yes ___ No ___

Hepatocellular Carcinoma (HCC)

A. Is the diagnosis unresectable HCC? Yes ___ No ___

B. Will tremelimumab-actl be given in conjunction with durvalumab? Yes ___ No ___

If diagnosis is not listed above, please indicate diagnosis: _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on tremelimumab-actl therapy?

Yes ___ No ___

3. Has the member experienced any adverse drug reactions related to tremelimumab-actl therapy?

Yes ___ No ___

A. If yes, please specify adverse reactions: _____

Additional Information: _____

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays. Please do not send in chart notes. Specific information will be requested if necessary.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit
Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.